IP Library › Granted Patent US 12,667,555
Granted Patent B2
US 12,667,555 · App. 18/440,869 · Granted Jun 30, 2026

Treatment of ovarian cancer with nirogacestat

Inventors: Allison Lim (Stamford, CT); Shinta Cheng (Stamford, CT); Todd Webster Shearer (Stamford, CT); Rex Williams (Stamford, CT); Kristin Patterson (Stamford, CT)
Assignee: SPRINGWORKS THERAPEUTICS, INC.
A61K31/417A61K9/0053
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,667,555
App. No.
18/440,869
Granted
Jun 30, 2026
Kind
B2
Abstract

The present disclosure relates to improved methods of treating ovarian cancer with nirogacestat.

Claims (52)

1 . A method for therapeutic treatment of ovarian cancer in a patient in need thereof comprising orally administering to the patient 150 mg (free base equivalent dose) of nirogacestat or a pharmaceutically acceptable salt thereof twice daily, wherein the patient has refractory or recurrent disease after previous treatment, and the method further comprises one or more of:

(a) upon the patient having Grade 3 or 4 diarrhea persisting for at least 3 days despite medical therapy, withholding the nirogacestat or pharmaceutically acceptable salt thereof until the diarrhea is resolved to no higher than a Grade 1 diarrhea or baseline and then restarting oral administration of the nirogacestat or pharmaceutically acceptable salt thereof at a dose of 100 mg (free base equivalent dose) twice daily;

(b) upon the patient having Grade 3 or 4 hypophosphatemia persisting for at least 3 days despite replacement therapy, withholding the nirogacestat or pharmaceutically acceptable salt thereof until the hypophosphatemia is resolved to no higher than a Grade 1 hypophosphatemia or baseline and then restarting oral administration of the nirogacestat or pharmaceutically acceptable salt thereof at a dose of 100 mg (free base equivalent dose) twice daily;

(c) upon the patient having Grade 3 or 4 hypokalemia despite replacement therapy, withholding the nirogacestat or pharmaceutically acceptable salt thereof until the hypokalemia is resolved to no higher than a Grade 1 hypokalemia or baseline and then restarting oral administration of the nirogacestat or pharmaceutically acceptable salt thereof at a dose of 100 mg (free base equivalent dose) twice daily;

(d) upon the patient having an alanine transaminase (ALT) or aspartate aminotransferase (AST) of 3 to 5 times upper limit of normal (ULN), withholding the nirogacestat or pharmaceutically acceptable salt thereof until the ALT, AST, or both are resolved to less than 3 times ULN or baseline and then restarting oral administration of the nirogacestat or pharmaceutically acceptable salt thereof at a dose of 100 mg (free base equivalent dose) twice daily; and

(e) upon the patient having an ALT or AST of greater than 5 times ULN, permanently discontinuing treatment with the nirogacestat or pharmaceutically acceptable salt thereof, wherein the nirogacestat or pharmaceutically acceptable salt thereof is nirogacestat dihydrobromide.

2 . The method of claim 1 , further comprising:

(f) for another severe adverse reaction, life-threatening adverse reaction, or persistent intolerable Grade 2 adverse event, withholding the nirogacestat or pharmaceutically acceptable salt thereof until the adverse reaction is resolved to no higher than a Grade 1 adverse reaction or baseline and then, after considering the potential benefit and likelihood of recurrence of the adverse reaction, (A) restarting oral administration of the nirogacestat or pharmaceutically acceptable salt thereof at a dose of 100 mg (free base equivalent dose) twice daily and (B) upon recurrence of the severe or life-threatening adverse reaction at the 100 mg (free base equivalent dose) twice daily dose, permanently discontinuing treatment with the nirogacestat or pharmaceutically acceptable salt thereof.

3 . The method of claim 1 , wherein the method comprises (a) upon the patient having Grade 3 or 4 diarrhea persisting for at least 3 days despite medical therapy, withholding the nirogacestat or pharmaceutically acceptable salt thereof until the diarrhea is resolved to no higher than a Grade 1 diarrhea or baseline and then restarting oral administration of the nirogacestat or pharmaceutically acceptable salt thereof at a dose of 100 mg (free base equivalent dose) twice daily.

4 . The method of claim 1 , wherein the method comprises (b) upon the patient having Grade 3 or 4 hypophosphatemia persisting for at least 3 days despite replacement therapy, withholding the nirogacestat or pharmaceutically acceptable salt thereof until the hypophosphatemia is resolved to no higher than a Grade 1 hypophosphatemia or baseline and then restarting oral administration of the nirogacestat or pharmaceutically acceptable salt thereof at a dose of 100 mg (free base equivalent dose) twice daily.

5 . The method of claim 1 , wherein the method comprises (c) upon the patient having Grade 3 or 4 hypokalemia despite replacement therapy, withholding the nirogacestat or pharmaceutically acceptable salt thereof until the hypokalemia is resolved to no higher than a Grade 1 hypokalemia or baseline and then restarting oral administration of the nirogacestat or pharmaceutically acceptable salt thereof at a dose of 100 mg (free base equivalent dose) twice daily.

6 . The method of claim 1 , wherein the method comprises (d) upon the patient having an ALT or AST of 3 to 5 times ULN, withholding the nirogacestat or pharmaceutically acceptable salt thereof until the ALT, AST, or both are resolved to less than 3 times ULN or baseline and then restarting oral administration of the nirogacestat or pharmaceutically acceptable salt thereof at a dose of 100 mg (free base equivalent dose) twice daily.

7 . The method of claim 1 , wherein the method comprises (e) upon the patient having an ALT or AST of greater than 5 times ULN, permanently discontinuing treatment with the nirogacestat or pharmaceutically acceptable salt thereof.

8 . The method of claim 1 , wherein the method comprises:

(a) upon the patient having Grade 3 or 4 diarrhea persisting for at least 3 days despite medical therapy, withholding the nirogacestat or pharmaceutically acceptable salt thereof until the diarrhea is resolved to no higher than a Grade 1 diarrhea or baseline and then restarting oral administration of the nirogacestat or pharmaceutically acceptable salt thereof at a dose of 100 mg (free base equivalent dose) twice daily;

(b) upon the patient having Grade 3 or 4 hypophosphatemia persisting for at least 3 days despite replacement therapy, withholding the nirogacestat or pharmaceutically acceptable salt thereof until the hypophosphatemia is resolved to no higher than a Grade 1 hypophosphatemia or baseline and then restarting oral administration of the nirogacestat or pharmaceutically acceptable salt thereof at a dose of 100 mg (free base equivalent dose) twice daily;

(c) upon the patient having Grade 3 or 4 hypokalemia despite replacement therapy, withholding the nirogacestat or pharmaceutically acceptable salt thereof until the hypokalemia is resolved to no higher than a Grade 1 hypokalemia or baseline and then restarting oral administration of the nirogacestat or pharmaceutically acceptable salt thereof at a dose of 100 mg (free base equivalent dose) twice daily;

(d) upon the patient having an ALT or AST of 3 to 5 times ULN, withholding the nirogacestat or pharmaceutically acceptable salt thereof until the ALT, AST, or both are resolved to less than 3 times ULN or baseline and then restarting oral administration of the nirogacestat or pharmaceutically acceptable salt thereof at a dose of 100 mg (free base equivalent dose) twice daily; and

(e) upon the patient having an ALT or AST of greater than 5 times ULN, permanently discontinuing treatment with the nirogacestat or pharmaceutically acceptable salt thereof.

9 . The method of claim 1 , wherein the method comprises:

(a) upon the patient having Grade 3 or 4 diarrhea persisting for at least 3 days despite medical therapy, withholding the nirogacestat or pharmaceutically acceptable salt thereof until the diarrhea is resolved to no higher than a Grade 1 diarrhea or baseline and then restarting oral administration of the nirogacestat or pharmaceutically acceptable salt thereof at a dose of 100 mg (free base equivalent dose) twice daily;

(b) upon the patient having Grade 3 or 4 hypophosphatemia persisting for at least 3 days despite replacement therapy, withholding the nirogacestat or pharmaceutically acceptable salt thereof until the hypophosphatemia is resolved to no higher than a Grade 1 hypophosphatemia or baseline and then restarting oral administration of the nirogacestat or pharmaceutically acceptable salt thereof at a dose of 100 mg (free base equivalent dose) twice daily;

(c) upon the patient having Grade 3 or 4 hypokalemia despite replacement therapy, withholding the nirogacestat or pharmaceutically acceptable salt thereof until the hypokalemia is resolved to no higher than a Grade 1 hypokalemia or baseline and then restarting oral administration of the nirogacestat or pharmaceutically acceptable salt thereof at a dose of 100 mg (free base equivalent dose) twice daily;

(d) upon the patient having an ALT or AST of 3 to 5 times ULN, withholding the nirogacestat or pharmaceutically acceptable salt thereof until the ALT, AST, or both are resolved to less than 3 times ULN or baseline and then restarting oral administration of the nirogacestat or pharmaceutically acceptable salt thereof at a dose of 100 mg (free base equivalent dose) twice daily;

(e) upon the patient having an ALT or AST of greater than 5 times ULN, permanently discontinuing treatment with the nirogacestat or pharmaceutically acceptable salt thereof; and

(f) for another severe adverse reaction, life-threatening adverse reaction, or persistent intolerable Grade 2 adverse event, withholding the nirogacestat or pharmaceutically acceptable salt thereof until the adverse reaction is resolved to no higher than a Grade 1 adverse reaction or baseline and then, after considering the potential benefit and likelihood of recurrence of the adverse reaction, (A) restarting oral administration of the nirogacestat or pharmaceutically acceptable salt thereof at a dose of 100 mg (free base equivalent dose) twice daily and (B) upon recurrence of the severe or life-threatening adverse reaction at the 100 mg (free base equivalent dose) twice daily dose, permanently discontinuing treatment with the nirogacestat or pharmaceutically acceptable salt thereof.

10 . The method of claim 1 , wherein upon the patient having a Grade 3 dermatologic reaction, withholding the nirogacestat or pharmaceutically acceptable salt thereof until the dermatologic reaction is resolved to no higher than a Grade 1 dermatologic reaction and then restarting oral administration of the nirogacestat or pharmaceutically acceptable salt thereof at a dose of 100 mg (free base equivalent dose) twice daily.

11 . The method of claim 1 , wherein the patient has a mutation in the adenomatous polyposis coli (APC) tumor suppressor gene.

12 . The method of claim 1 , wherein the patient has a mutation in the CTNNB1 (β-catenin) gene.

13 . The method of claim 1 , wherein the patient was previously treated with a tyrosine kinase inhibitor.

14 . The method of claim 1 , wherein the patient is an adult.

15 . The method of claim 1 , wherein the patient is a post- menopausal woman.

16 . The method of claim 1 , wherein gastric acid reducing agents are avoided or administered 4 hours after administration of the nirogacestat or pharmaceutically acceptable salt thereof.

17 . A method for therapeutic treatment of ovarian cancer in a treatment naïve patient comprising orally administering to the patient 150 mg (free base equivalent dose) of nirogacestat or a pharmaceutically acceptable salt thereof twice daily, wherein the ovarian cancer is an ovarian granulosa cell tumor (OvGCT).

18 . The method of claim 1 , wherein the patient, after initial administration of 150 mg (free base equivalent dose) of nirogacestat or a pharmaceutically acceptable salt thereof, exhibits a C max of nirogacestat of from about 480 to about 950 ng/ml.

19 . The method of claim 1 , wherein the patient, after initial administration of 150 mg (free base equivalent dose) of nirogacestat or a pharmaceutically acceptable salt thereof, exhibits a C max of nirogacestat of from about 550 to about 1100 ng/ml.

20 . The method of claim 19 , wherein the patient, after initial administration of 150 mg (free base equivalent dose) of nirogacestat or a pharmaceutically acceptable salt thereof, exhibits a C max of nirogacestat of from about 600 to about 800 ng/mL.

21 . The method of claim 1 , wherein the patient, after initial administration of 150 mg (free base equivalent dose) of nirogacestat or a pharmaceutically acceptable salt thereof, exhibits an AUC last of nirogacestat of less than 4000 ng·h/mL.

22 . The method of claim 1 , wherein the patient, after initial administration of 150 mg (free base equivalent dose) of nirogacestat or a pharmaceutically acceptable salt thereof, exhibits an AUC last of nirogacestat of from about 2000 to about 4000 ng·h/mL.

23 . The method of claim 1 , wherein the patient, after initial administration of 150 mg (free base equivalent dose) of nirogacestat or a pharmaceutically acceptable salt thereof, exhibits an AUC inf of nirogacestat of from about 2200 to about 4800 ng·h/mL.

24 . The method of claim 23 , wherein the patient, after initial administration of 150 mg (free base equivalent dose) of nirogacestat or a pharmaceutically acceptable salt thereof, exhibits an AUC inf of nirogacestat of from about 2200 to about 3300 ng·h/mL.

25 . The method of claim 1 , wherein the patient exhibits, at steady state exposure from administration of 150 mg (free base equivalent dose) of nirogacestat or a pharmaceutically acceptable salt thereof twice daily, a C max of nirogacestat of from about 300 to 700 ng/mL.

26 . The method of claim 25 , wherein the patient exhibits, at steady state exposure from administration of 150 mg (free base equivalent dose) of nirogacestat or a pharmaceutically acceptable salt thereof twice daily, a C max of nirogacestat of from about 400 to about 600 ng/mL.

27 . The method of claim 1 , wherein the patient exhibits, at steady state exposure from administration of 150 mg (free base equivalent dose) of nirogacestat or a pharmaceutically acceptable salt thereof twice daily, an AUC tau of nirogacestat of from about 2200 to about 4800 ng·h/mL.

28 . The method of claim 27 , wherein the patient exhibits, at steady state exposure from administration of 150 mg (free base equivalent dose) of nirogacestat or a pharmaceutically acceptable salt thereof twice daily, an AUC tau of nirogacestat of from about 3000 to about 3700 ng·h/mL.

29 . A method for therapeutic treatment of ovarian cancer in a patient in need thereof comprising orally administering to the patient 150 mg (free base equivalent dose) of nirogacestat or a pharmaceutically acceptable salt thereof twice daily, wherein the patient has refractory or recurrent disease after previous treatment, and the method further comprises one or more of:

(a) upon the patient having Grade 3 or 4 diarrhea persisting for at least 3 days despite medical therapy, withholding the nirogacestat or pharmaceutically acceptable salt thereof until the diarrhea is resolved to no higher than a Grade 1 diarrhea or baseline and then restarting oral administration of the nirogacestat or pharmaceutically acceptable salt thereof at a dose of 100 mg (free base equivalent dose) twice daily:

(b) upon the patient having Grade 3 or 4 hypophosphatemia persisting for at least 3 days despite replacement therapy, withholding the nirogacestat or pharmaceutically acceptable salt thereof until the hypophosphatemia is resolved to no higher than a Grade 1 hypophosphatemia or baseline and then restarting oral administration of the nirogacestat or pharmaceutically acceptable salt thereof at a dose of 100 mg (free base equivalent dose) twice daily:

(c) upon the patient having Grade 3 or 4 hypokalemia despite replacement therapy, withholding the nirogacestat or pharmaceutically acceptable salt thereof until the hypokalemia is resolved to no higher than a Grade 1 hypokalemia or baseline and then restarting oral administration of the nirogacestat or pharmaceutically acceptable salt thereof at a dose of 100 mg (free base equivalent dose) twice daily;

(d) upon the patient having an alanine transaminase (ALT) or aspartate aminotransferase (AST) of 3 to 5 times upper limit of normal (ULN), withholding the nirogacestat or pharmaceutically acceptable salt thereof until the ALT, AST, or both are resolved to less than 3 times ULN or baseline and then restarting oral administration of the nirogacestat or pharmaceutically acceptable salt thereof at a dose of 100 mg (free base equivalent dose) twice daily; and

(e) upon the patient having an ALT or AST of greater than 5 times ULN, permanently discontinuing treatment with the nirogacestat or pharmaceutically acceptable salt thereof, wherein the ovarian cancer is an ovarian granulosa cell tumor (OvGCT).

30 . The method of claim 1 , wherein the patient exhibits hyperestrogenism.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2024
From: LIM, ALLISON; CHENG, SHINTA; SHEARER, TODD WEBSTER; WILLIAMS, REX; PATTERSON, KRISTIN
To: SPRINGWORKS THERAPEUTICS, INC.
Reel/Frame 066459/0931 →
Continuity (6)
Continuation 18543022 · Dec 18, 2023
Continuation In Part 18491525 · Oct 20, 2023
Continuation In Part 18320547 · May 19, 2023
Provisional Application 63365193 · May 23, 2022
Provisional Application 63365125 · May 20, 2022
Related Publication 20240180874A1 · Jun 6, 2024
References Cited (66)
US 7465800B2 · Jaworsky et al. · 2008 [cited by applicant]
US 7795447B2 · Brodney et al. · 2010 [cited by applicant]
US 8399469B2 · Bando et al. · 2013 [cited by applicant]
US 10590087B1 · Greer et al. · 2020 [cited by applicant]
US 10941118B2 · Greer et al. · 2021 [cited by applicant]
US 11872211B2 · Lim et al. · 2024 [cited by applicant]
US 20050215610A1 · Brodney et al. · 2005 [cited by applicant]
US 20190185559A1 · Russell et al. · 2019 [cited by applicant]
US 20210040045A1 · Greer et al. · 2021 [cited by applicant]
CA 2991096A1 · 2017 [cited by applicant]
CN 112843238A · 2021 [cited by examiner]
WO 2005092864A1 · 2005 [cited by applicant]
WO 2014191894A1 · 2014 [cited by applicant]
WO 2015092614A1 · 2015 [cited by applicant]
WO 2015171003A1 · 2015 [cited by applicant]
WO 2016046530A1 · 2016 [cited by applicant]
WO 2016198374A1 · 2016 [cited by applicant]
WO 2018045273A2 · 2018 [cited by applicant]
WO 2019053727A1 · 2019 [cited by applicant]
WO 2020208572A1 · 2020 [cited by applicant]
WO 2021146604A1 · 2021 [cited by applicant]
WO 2021183934A1 · 2021 [cited by applicant]
WO 2021195362A1 · 2021 [cited by applicant]
WO 2023049694A1 · 2023 [cited by applicant]
WO 2023064872A1 · 2023 [cited by applicant]
WO 2023081830A2 · 2023 [cited by applicant]
A Phase I Trial of PF-03084014 in Patients with Advanced Solid Tumor Malignancy and T-cell Lymphoblastic Leukemia/ Lymphoblastic Lymphoma. ClinicalTrials.gov ID:NCT00878189. (Study Concluded Nov. 22, 2016). (Year: 2016). [cited by applicant]
“A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumor/ Aggressive Fibromatosis (DT /AF)”, Protocol NIR-DT-301, Dec. 2018, 7 pages. [cited by applicant]
“CAS Scifinder Nirogacestat—Predicted Solubility”, American Chemical Society (ACS); (CAS registry No. 1290543-63-3) accessed online 2023:1-5. [cited by applicant]
NIH-NCI, “Common terminology criteria for adverse events”, v. 5.0, 2017, p. 1-146. [cited by applicant]
Altman, Ben, et al., The Desmoid Tumor Working Group, “The management of desmoid tumours: A joint global consensus-based guideline approach for adult and pediatric patients”, European Journal of Cancer, 2020, 127:96-107… [cited by applicant]
Bauer, T.M. , “Clinical management of adverse events associated with lorlatinib”, The Oncologist, 2019, 24:1103-1110. [cited by applicant]
Chi, K.N. , et al., “A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel”, Canadian Urologic Oncology Group study P07a, Annals of Oncology, 20… [cited by applicant]
Coyne, G.O., “Activity of PF-03084014 in adults with desmoid tumors/aggressive fibromatosis”, J Clin Oneal 34 (2016) Poster# 11028. [cited by applicant]
Coyne, G.O., “Phase II Trial of the gamma-secretase inhibitor nirogacestat (PF-03084014) in adults with desmoid tumors/aggressive fibramatosis”, NCI Protocol # 14-C-0007; Version Date Dec. 3, 2021 NCT No. NCT01981551, 1… [cited by applicant]
Du Fy , et al., “Targeting cancer stem cells in drug discovery: Current state and future perspectives”, World J Stem Cells. Jul. 26, 2019;11 (7):398-420. (Year: 2019). [cited by applicant]
Gounder, M , et al., “Nirogacestat, a y-Secretase Inhibitor for Desmoid Tumors”, N Engl J Med 2023, 388:898-912 DOI: 10.1056/NEJMoa2210140). [cited by applicant]
Hosea, N.A. , et al., “Predicting pharmacokinetic profiles using in silica derived parameters”, Molecular Pharmaceutics, 2013, 10:1207-1215. [cited by applicant]
Irusta, et al., Biol Reprod. 2013, 89(1):9, doi: 10.1095/biolreprod.113.108100. [cited by applicant]
Kasper, B , et al., “Desmoid tumors: to treat or not to treat, that is the question”, Cancer, 2020, 126(24):5213-5221. [cited by applicant]
Kummar, Shivaani, et al., “Clinical Activity of the y-Secretase Inhibitor PF-03084014 in Adults with Desmoid Tumors (Aggressive Fibromatosis)”, J Clin Oncology, 2017, 34(14):1561-1569. [cited by applicant]
Ma, C, “Protocol Administrative Letter”, 2020, 1-87. [cited by applicant]
Merck, “A Parallel-Group, Double-Blind, Long Term Safety and Efficacy Trial of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD)”, p. 1-85, 2019 © https:/… [cited by applicant]
Messersmith , et al., “A Phase I, dose-finding study in patients with advanced solid malignancies of the oral y-secretase inhibitor PF-03084014”. Clin Cancer Res. Jan. 1, 2015;21(1):60-7. (Year: 2015). [cited by applicant]
Miner, P.B. , et al., “Comparison of gastric pH with omeprazole magnesium 20.6 mg (Prilosec OTC) o.m. famotidine 10 mg, (Pepcid AC) b.d. and famotidine 20 mg b.d. over 14 days of treatment”, Alimentary Pharmacology & Th… [cited by applicant]
Shah , et al., N Engl J Med. 2009, 360(26):2719-29, doi: 10. 1056/NEJMoa0902542. [cited by applicant]
X Li , et al., “The molecular mechanism of ovarian granulosa cell tumors”, J Ovarian Res 11, 13 (2018) (Year: 2018). [cited by applicant]
Study Details—NIR-DT-301, Nirogacestat for Adults With Desmoid Tumor/ Aggressive Fibromatosis {DT / AF), SpringWorks Therapeutics, Inc., Dec. 2018 7 pages. [cited by applicant]
“International Search Report and written opinion issued in PCT/US2023/022881 on Oct. 5, 2023”. [cited by applicant]
“International Search Report issued in PCT/US2022/079309 on Apr. 7, 2023”. [cited by applicant]
“NIH-NCI Common terminology criteria for adverse events. (2022); p. 1-146”. [cited by applicant]
“PUBCHEM-SID:383689933 Deposit Date: May 8, 2019 (08.05.2019) pp. 1-6; p. 2”. [cited by applicant]
Bauer, T.M. , “Clinical management of adverse events associated with lorlatinib”, The oncologist 24.8 (2019): 1103-1110. [cited by applicant]
Chi, K.N. , “A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel”, Canadian Urologic Oncology Group study P07a. Annals of oncology 23.1 (2012)… [cited by applicant]
Coyne, G.O. , “Phase II Trial of the gamma-secretase inhibitor nirogacestat (PF-03084014) in adults with dismoid tumors/aggressive fibramatosis”, NCI Protocol # 14-C-0007; Version Date Dec. 3, 2021 NCT No. NCT01981551; … [cited by applicant]
Coyne , “Phase II Trial of the -secretase Inhibitor PF-03084014 in Adults with Desmoid Tumors/Aggressive Fibromatosis 1-66”, ClinicalTrials.gov. Web. Apr. 8, 2019; p. 3, Objectives, Study Design; p. 13, second paragraph… [cited by applicant]
Grounder, M , et al., “Nirogacestat, a y-Secretase Inhibitor for Desmoid Tumors”, N Engl J Med 2023, 388:898-912 DOI: 10.1056/NEJMoa2210140). [cited by applicant]
Hosea, N .A. , “Predicting pharmacokinetic profiles using in silica derived parameters”, Molecular pharmaceutics 10.4 (2013): 1207-1215. [cited by applicant]
Kasper, B , “Desmoid tumors: to treat or not to treat, that is the question”, Cancer 126.24 (2020): 5213-5221. [cited by applicant]
Kummar S., et al., “Clinical Activity of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis),” American Society of Journal of Clinical Oncology, May 10, 2017, vol. 35, No. 1… [cited by applicant]
Curigliano G., et al., “Phase I Dose-finding Study of the Gamma Secretase Inhibitor PF-03084014 (PF-4014) in Combination with Docetaxel in Patients (pts) with Advanced Triple-negative Breast Cancer (TNBC),” Journal of C… [cited by applicant]
Kaufman M.L., et al., “Transcriptional Profiling of Murine Retinas Undergoing Semi-Synchronous Cone Photoreceptor Differentiation,” Developmental Biology, 2019, vol. 453, pp. 155-167. [cited by applicant]
Shang H., et al., “Targeting the Notch Pathway: A Potential Therapeutic Approach for Desmoid Tumors,” Cancer, John Wiley and Sons Inc., United States, Nov. 15, 2015, vol. 121, No. 22, pp. 4088-4096. [cited by applicant]
Wei P., et al., “Evaluation of Selective Gamma-Secretase Inhibitor PF-03084014 for its Antitumor Efficacy and Gastrointestinal Safety to Guide Optimal Clinical Trial Design,” Molecular Cancer Therapeutics, American Asso… [cited by applicant]
Silverman R.B., “Lead Modification: Drug Design and Development,” The Organic Chemistry of Drug Design and Drug Addiction, 2nd Edition, Elsevier, United States, 2004, pp. 29-32 (6 Pages), Hayhurst J., (Senior Publishing… [cited by applicant]
Takahashi T., et al., “Safety and Efficacy of Gamma-Secretase Inhibitor Nirogacestat (PF-03084014) in Desmoid Tumor: Report of Four Pediatric/Young Adult Cases,” Pediatric Blood Cancer, 2020, vol. 67: e28636, 6 Pages. [cited by applicant]